John Day, MD
Neuromuscular Medicine · Stanford, CANPI 1447291992
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 17 manufacturers reported payments, led by Novartis Gene Therapies, Inc. (fka Avexis, Inc.) at 32.8% of the total. Reporting peaked in 2019 at $73,609 and has fallen 70.6% since, to $21,660 in 2025. Among neuromuscular medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 338 payments — averaging $870.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$96K
- Sarepta Therapeutics, Inc.$61K
- Biogen$41K
- F. Hoffmann-la Roche AG$39K
- Genentech USA, Inc.$19K
- Vertex$8K
- plus $29K from 11 others
Across 726 payments — averaging $19,480 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$7.1M
- Novartis Gene Therapies, Inc. (fka Avexis, Inc.)$1.7M
- Hoffmann-la Roche Limited$1.5M
- Sarepta Therapeutics, Inc.$1.4M
- Sanofi$1.2M
- F. Hoffmann-la Roche AG$378K
- plus $839K from 7 others
What the payments were for
- Consulting fees$136,11646%
- Speaking & faculty fees$53,33818%
- Travel & lodging$51,93518%
- Food & beverage$5,0822%
- Education$47,76916%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis Gene Therapies, Inc. (fka Avexis, Inc.) | 171 | $96,437 |
| Sarepta Therapeutics, Inc. | 44 | $61,160 |
| Biogen | 35 | $41,471 |
| F. Hoffmann-la Roche AG | 40 | $39,410 |
| Genentech USA, Inc. | 16 | $19,012 |
| Vertex | 3 | $7,875 |
| Insmed, Inc. | 7 | $6,442 |
| Sanofi | 2 | $3,975 |
| Novartis Pharma AG | 1 | $3,362 |
| Roche Products Limited | 5 | $2,905 |
| Biomarin Pharmaceutical Inc. | 4 | $2,798 |
| Sanofi US Services Inc. | 1 | $2,725 |
| Merck | 1 | $2,640 |
| Novartis | 3 | $1,866 |
| NS Pharma, Inc. | 1 | $1,326 |
| Argenx US, Inc. | 1 | $625 |
| Genentech, Inc. | 3 | $212 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZOLGENSMA$88,438
- SPINRAZA$29,011
- Non-Covered Product$26,575
- Exondys 51$15,690
- EVRYSDI$8,008
- Elevidys$3,375
- OCREVUS$1,800
- VILTEPSO$1,326
- NEXVIAZYME$1,250
How this compares
$294,240 in reported general payments places this provider in the 90th percentile of 44 neuromuscular medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SkyclarysOmaveloxolone | 13 | $406,626 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenSkyclarys | $41,471 | $406,62613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 44 neuromuscular medicine providers in California.
Other neuromuscular medicine in Stanford
- Yuen SoStanford$7K
- Jacinda SampsonStanford$4K
- Sarada SakamuriStanford$404
- Kathie LinStanford$214
- Maxwell GreeneStanford$111
- Kenneth LeungStanford$15
- Samir MacwanRancho Mirage$983K
- Ali HabibOrange$445K
- Tahseen MozaffarOrange$428K
- Jeffrey RosenfeldFresno$361K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.